Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
93 studies found for:    weill | "RNA Virus Infections"
Show Display Options
Rank Status Study
1 Terminated Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
Condition: Hepatitis C
Interventions: Biological: Interleukin 2;   Drug: Ribavirin;   Biological: Pegylated Interferon Alpha;   Biological: Inteleukin-2;   Drug: Ribavirin + Pegylated interferon-alpha
2 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
3 Completed
Has Results
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
Conditions: HIV-Associated Lipodystrophy Syndrome;   Insulin Resistance;   HIV Infections;   Metabolic Syndrome X;   Body Weight Changes
Interventions: Drug: Rosiglitazone;   Drug: Recombinant human growth hormone + rosiglitazone
4 Enrolling by invitation Hepatitis C Treatment in Underserved Populations
Conditions: Chronic Hepatitis C;   Illicit Drug Use
Intervention: Other: Collaborative, multidisciplinary, integrated care
5 Terminated Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
Conditions: Anemia;   Neutropenia;   Hepatitis C Virus;   HIV Infections
Intervention: Drug: erythropoietin, GCSF
6 Completed The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
Conditions: Male Circumcision;   HIV Prevention;   HIV Infections
Intervention: Device: Shang Ring circumcision
7 Completed
Has Results
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Condition: Hepatitis C
Interventions: Drug: Telaprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
8 Completed Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects
Condition: Chronic Hepatitis C
Intervention: Drug: Ribavirin, PEG-Intron
9 Terminated Armodafinil for Patients Starting Hepatitis C Virus Treatment
Condition: Hepatitis C
Interventions: Drug: Armodafinil;   Drug: Placebo Comparator
10 Completed Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Condition: HIV Infections
Interventions: Biological: ALVAC HIV vaccine (vCP1452);   Drug: Interleukin-2
11 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
12 Completed A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs
Condition: HIV Infections
Interventions: Drug: Indinavir sulfate;   Drug: Nevirapine;   Drug: Lamivudine;   Drug: Stavudine;   Drug: Didanosine
13 Completed Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
14 Completed
Has Results
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
Condition: HIV Infections
Interventions: Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate
15 Completed Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Drug: Aldesleukin
16 Active, not recruiting An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Condition: Parainfluenza
Interventions: Drug: DAS181-F02 Dry Powder in Bulk;   Drug: DAS181-F02 Nebulized Formulation Inhaled Dose
17 Active, not recruiting A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Condition: Parainfluenza
Interventions: Drug: DAS181 dry powder, formulation F02;   Drug: Lactose Placebo
18 Recruiting IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence
Condition: HIV Infection
Intervention:
19 Completed
Has Results
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Condition: HIV-1 and Hepatitis C Co-Infection
Interventions: Drug: pioglitazone;   Drug: peginterferon;   Drug: ribavirin
20 Recruiting Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Condition: Liver Disease
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: sofosbuvir;   Drug: Ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.